---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Incidence"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Incidence. Topics: Australia: cumulative incidence by age, Australian Rett Syndrome Database; Australia: cumulative risk of diagnosis and birth prevalence, females born 1976 to 2006; France: incidence of Rett syndrome with an MECP2 variant; Serbia: incidence per female live births, 1981 to 2012; 2 further topics. 6 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/incidence"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of Rett syndrome

<a id="topic-2.2.1.2.1-1"></a>

### Australia: cumulative incidence by age, Australian Rett Syndrome Database

> “the cumulative incidence was 1.09 per 10,000 females by 12 years of age. The cumulative incidence by the age of 5 years increased from .39 per 10,000 in the 1980 to 1984 cohort to .76 per 10,000 in birth cohorts beyond 1984.”

Source: [Laurvick et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16615965/)

<a id="topic-2.2.1.2.1-2"></a>

### Australia: cumulative risk of diagnosis and birth prevalence, females born 1976 to 2006

> “The population-based Australian Rett Syndrome Database was used to identify a total of 349 verified Rett syndrome females born 1976-2006 and diagnosed 1982-2008.”
> “The cumulative risk of diagnosis had almost doubled by 32 y of age [1/8,905 or 11.23 per 100,000 person-years (95% CI, 10.03–12.45)] in comparison with 5 y of age [1/15,361 or 6.51 per 100,000 person-years (95% CI, 5.65–7.39)].”
> “The birth prevalence varied by birth year (Table 2), peaking for those born in the early to mid 1990s.”

Source: [Fehr et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3152673/)

| Year of birth | Number of cases | Number of cases per 100,000 female births (95% CI) |
| --- | --- | --- |
| Overall (1976-2006) | “349” | “9.37 (8.41-10.41)” |

Source: [Fehr et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3152673/)

<a id="topic-2.2.1.2.1-3"></a>

### France: incidence of Rett syndrome with an MECP2 variant

> “The present study, based on a large cohort of 424 patients with Rett syndrome, found that the incidence of this disease with a MECP2 mutation varied between 0.43 to 0.71 per 10,000 females.”
> “Given that this is a minimum incidence because complete inventory was not possible, this study of patients with Rett syndrome reinforces the fact that the great majority of patients with Rett syndrome have a MECP2 mutation.”

Source: [Bienvenu et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16647997/)

<a id="topic-2.2.1.2.1-4"></a>

### Serbia: incidence per female live births, 1981 to 2012

> “From 1981 to 2012, RTT has been diagnosed in 102 girls in Serbia. Incidence of RTT in Serbia is estimated at 0.586:10,000 female live births.”

Source: [Sarajlija et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25571926/)

<a id="topic-2.2.1.2.1-5"></a>

### United States: annual incidence of diagnosis in claims data, 2018 and 2019

> “Overall, the annual incidence of RTT in this dataset was an estimated 0.34 and 0.23 per 10,000 enrollees in 2018 and 2019, respectively (Table 2). Among female patients, the annual incidence was 0.43 and 0.31 per 10,000 female enrollees in 2018 and 2019, respectively, while among male patients, it was 0.22 and 0.13 per 10,000 male enrollees, respectively. Stratified by age, incidence estimates per 10,000 enrollees for the pediatric population in 2018 and 2019 were 1.40 and 1.25, respectively, for ages 0–4 years; 1.53 and 0.92 for ages 5–10 years; and 1.00 and 0.67 for ages 11–17 years (Table 3).”
> “Annual incidence was calculated as the proportion of patients newly diagnosed with RTT among the total number of at-risk patients at the start of the study period. A minimum 6-month washout period was used to ensure at-risk enrollees and incident cases did not have a RTT diagnosis.”

Source: [May et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10071755/)

<a id="topic-2.2.1.2.1-6"></a>

### Canada: incident cases in Ontario administrative data, 2017 to 2023

> “Incident cases were identified between September 2017 and August 2023, while prevalent cases were captured from April 2002 to August 2023.”
> “From September 2017 to August 2023, 57 incident cases and 257 prevalent cases were reported in Ontario.”

Source: [Bond et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41267498/)

> “According to sponsor-submitted information, there are approximately 8 to 12 incident cases diagnosed annually in Ontario.”

Source: [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
